Sam Rasty

Sam Rasty has a diverse work experience spanning over two decades. Sam currently holds the position of Chief Executive Officer and Board Director at Sequence Bio. Prior to that, they were a Board Director at Oxford Biomedica, where they played a key role in their transformation into a world leader in gene and cell therapy viral vector manufacturing. Sam also served as the President, CEO, and Board Director at PlateletBio, where they led the strategic pivot and expansion of their R&D platform.

Earlier in their career, Sam was the Chief Operating Officer at Homology Medicines, where they played a crucial role in their IPO and clinical entry as a genetic medicines company. Sam also served as the Vice President and Head of New Products at Shire, where they led the formulation of a robust re-prioritization of disease areas for the R&D pipeline. Sam has also worked at Endo as the Director of Corporate Development and Director of Strategic Marketing and at GlaxoSmithKline as the Director of Portfolio Management.

Before their corporate roles, Sam worked as a Managing Director at ConRas Healthcare Consulting, providing consulting services to biotech and pharma companies. Sam also had roles at Genovo, Inc. as a Manager and Scientist. Sam's experience spans various areas including strategy, business development, commercial assessments, and portfolio management.

Sam Rasty completed a Postdoctoral Fellowship in Molecular Genetics, Virology, and Gene Therapy at the University of Pittsburgh School of Medicine from 1990 to 1996. Sam then pursued an MBA at Villanova University, graduating between 2000 and 2002. Prior to that, they obtained a Ph.D. in Biochemistry from Louisiana State University, attending from 1984 to 1989.